Beyond Air (XAIR) Registration Filing summary

Company overview and business model

• Commercial-stage medical device and biopharmaceutical company focused on nitric oxide (NO) generators and delivery systems, primarily the LungFit® platform for respiratory conditions.

• LungFit® PH received FDA approval in June 2022 for treating persistent pulmonary hypertension of the newborn (PPHN) and CE mark in Europe in November 2024 for broader indications.

• Additional programs include Beyond Cancer (targeting solid tumors with ultra-high concentration NO) and NeuroNOS (developing nNOS inhibitors for neurological conditions such as autism spectrum disorder).

• Competitive advantages include on-demand NO generation from ambient air, eliminating the need for high-pressure cylinders and reducing hospital staff burden.

Financial performance and metrics

• Recent financing includes a $20 million equity purchase agreement and a $12.05 million secured promissory note with Streeterville Capital, LLC.

• Amended and restated loan agreement provided an additional $2 million term loan and new warrants.

• As of January 22, 2026, 10,529,344 shares of common stock were outstanding, with up to 17,865,990 shares expected post-offering, assuming full warrant exercise.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling stockholders; proceeds from any cash exercise of warrants will be used for general corporate purposes and working capital.